Qualifying injuries are severe dosing injuries that sent a person to the hospital: seizure, loss of consciousness, coma and death from too much insulin, plus diabetic ketoacidosis and diabetic coma from too little insulin. Legal reporting says lawsuits focus on Type 1 diabetes users hospitalized after one of these dosing errors. A MiniMed pump is a small wearable device that delivers insulin during the day. The claims link two failure modes: a loose reservoir that cannot lock, and a battery failure that shuts the pump down.
Official resources:
- Read the official notice from FDA — Use this primary source to verify the official announcement.
- Explore the official data from FDA — Use this primary source to review the underlying data.
Table of Contents
- Which pumps and defects are involved?
- When does low blood sugar qualify?
- When does high blood sugar qualify?
- What can block a claim and what should you do?
Which pumps and defects are involved?
The U.S. Food and Drug Administration posted the Class 1 recall record on Feb. 7, 2020, after Medtronic started the recall Nov. 21, 2019.
It covers MiniMed 630G, 670G and 640G pumps with clear retainer rings. The U.S. Food and Drug Administration described the 2024 battery safety alert as a July 31, 2024 field action for MiniMed 600/700-series pumps. It includes 630G, 670G, 770G and 780G for shortened battery life and unexpected shutdown, classified as Class I.
When does low blood sugar qualify?
The U.S. Food and Drug Administration explained the reservoir defect as a broken or missing retainer ring.
The ring leaves the reservoir loose and unable to lock, so the pump can deliver too much or too little insulin. LegalClarity reports over-delivery can cause hypoglycemia with seizure, loss of consciousness, coma or death. TorHoerman Law reports regulators logged 26,421 complaints, 2,175 injuries and one death at the time of that recall.
When does high blood sugar qualify?
LegalClarity reports under-delivery can cause hyperglycemia progressing to diabetic ketoacidosis. For the battery issue, Medtronic reported 170 cases of hyperglycemia over 400 mg/dL and 11 cases of diabetic ketoacidosis, according to the FDA, from January 2023 to September 2024.
Legal reporting says suits focus on Type 1 users hospitalized after dosing errors. The alleged injuries include severe hypo- and hyperglycemia, ketoacidosis, diabetic coma, seizures and death.
What can block a claim and what should you do?
LegalClarity reports federal courts dismissed Warmoth in June 2023 and Rieger in January 2025 as preempted by FDA premarket approval. It also reports no global settlement by mid-2026. Mass Device and the FDA advise three immediate safety checks for users:.
- Stop use if the reservoir does not lock.
- Follow pump battery alerts closely.
- Contact Medtronic if battery life shortens.